VRDN
Viridian Therapeutics, Inc. $19.00 -2.06% 2026-10-05 종가 기준핵심 지표
yfinance 기준분기 실적
매출·순이익 · yfinance연간 실적 5년
SEC 10-K · 회계연도 · 달러잉여현금흐름 $-0.3B
잉여현금흐름 $-0.2B
잉여현금흐름 $-0.2B
잉여현금흐름 $-0.1B
잉여현금흐름 $-0.1B
EPS 서프라이즈
최근 4분기 · 실제 vs 예상수익성·성장
최근 12개월 기준사업 개요
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.